Virax Biolabs
VRAX
2 hedge funds and large institutions have $77.6K invested in Virax Biolabs in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
0.71% less ownership
Funds ownership: 0.85% → 0.13% (-0.71%)
50% less funds holding
Funds holding: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
62% less capital invested
Capital invested by funds: $202K → $77.6K (-$125K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$112K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$193K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
-$8.96K |
| 3 |
FFA
Farther Finance Advisors
San Francisco,
California
|
-$4 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4 |
VRAX Hedge Fund Activity: Q2 2026 in Review
2 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2026, worth a combined $77.6K — down 62% from $202K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VRAX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Jane Street, opening a new position worth an estimated $112K. The largest seller was Armistice Capital, exiting entirely with an estimated $193K sold.
- 2 institutional investors held Virax Biolabs (VRAX) as of Q2 2026, down from 4 in Q1 2026.
- Funds reported $77.6K of Virax Biolabs stock for Q2 2026, down 62% quarter-over-quarter.
- 2 funds opened new Virax Biolabs positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest Virax Biolabs buyer in Q2 2026 was Jane Street, an estimated $112K added.
- The largest Virax Biolabs seller in Q2 2026 was Armistice Capital, an estimated $193K sold.
Based on aggregated 13F filings for Q2 2026.